ClinicalTrials.gg
RecruitingNCT06443320VIDEOTSAUpdated Feb 6, 2025

Evaluation of the Videodrama Therapeutic Device for Children with Autism Spectrum Disorders

An interventional study of patient included in experimental groupe will view the video excerpt, a playtime, a drawing activities in Autism Spectrum Disorder (ASD), sponsored by Centre Hospitalier Intercommunal Robert Ballanger. Recruiting at 1 site in France. Open to participants aged 3 Years to 15 Years. Per ClinicalTrials.gov, last updated 2025-02-06.

Primary conditionAutistic DisorderRegistry: Autism Spectrum DisorderReclassifiedWhy we changed it
Registry
Autism Spectrum Disorder — the first condition term the registry derived for this study.
ClinicalTrials.gg
Autistic Disorder
Why
  1. The study's listed conditions name Autistic Disorder, a narrower term within Autism Spectrum Disorder.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Intercommunal Robert Ballanger · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Dec 2023, registered May 2024).
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
3 Years to 15 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Autistic Disorder with a site in France — 10 open to participants now, 10 under way, 1 of them phase 3. Autistic Disorder · France.

Planned enrollment
31st of 37
30 · median 60
Started
2023
with 4 others
No phase
26 of 50
7 open now
Registered
45th of 50
by date

Among the 50 studies in Autistic Disorder with a site in France, this one is the 31st largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2023, is one of 26 with no phase, and was the 45th registered.

Autistic Disorder

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

Browse Autistic Disorder studies →

Open to participants now

10 of the 50 studies in Autistic Disorder with a site in France are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 184 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 144 (78%) stop at 75 or younger; 150 take children under 18; 56 take healthy volunteers.

This study: 3 Years to 15 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Autistic Disorder with a site in France, or all of them as a file.
02

Study summary

Autism spectrum disorder (ASD) is a neurodevelopmental disorder (Valerie, Sperenza, 2009) that begins early in development, characterized by persistent deficits in communication and social interactions across various contexts and restricted, repetitive patterns of behavior, interests, or activities. These symptoms significantly impact social, school/professional functioning, or other important areas and are not better explained by intellectual disability or global developmental delay (American Psychiatric Association, 2013).

Read the detailed description

Currently, managing children with ASD emphasizes compensating for communication and social interaction disabilities. Communication tools like PECS or Makaton and social skills groups have shown effectiveness but have limitations, particularly not addressing sensory atypicalities seen in children with ASD. These sensory atypicalities are evident when children watch videos on screens. The idea is to use video to understand the sensory experiences of children with ASD and help them move away from an isolated relationship with screens. New technologies can further isolate children with ASD in their autistic sphere. The hypothesis is that observing these children with screens will provide better understanding of their sensory experiences and improve therapeutic support towards play and interaction with others

03

Conditions studied

  • Autism Spectrum Disorder (ASD)

Browse trials for

Keywords

  • autism
  • videodrama
04

In context

Autistic Disorder Reclassified

1,035 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.

This study's planned enrollment of 30 is below the median of 50 across 814 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

Centre Hospitalier Intercommunal Robert Ballanger is the lead sponsor of 6 studies on the registry; 4 are open to participants now.

Compared within Autistic Disorder, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autism Spectrum Disorder. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
3 Years to 15 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children aged 3 to 15 years.
  • Clinically confirmed ASD by a psychiatrist.
  • Parental or legal guardian consent for participation.
  • Child showing a strong interest in screens and/or video content.
  • Ability to tolerate the presence of other children.
  • Minimum of 18 video drama sessions.
  • Not having benefited from disease care in the past.
  • Affiliation to a social security system

Exclusion criteria

Exclusion Criteria:

  • No ASD diagnosis.
  • Younger than 3 or older than 15 at the study start.
  • No interest in screens or video content.
  • Parental or legal guardian refusal for participation.
  • Dropping out before completing 18 sessions.
  • Patient having benefited a disease care in the past
06

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Group of young ASD patients receiving videodrama sessions and interviews

    Children participating in videodrama sessions, one per week for 9 sessions.

    Other: patient included in experimental groupe will view the video excerpt, a playtime, a drawing activities

  • No intervention
    Cohort of ASD patients not receiving videodrama but receiving care in participating units

    Patients included in the cohort will be managed as part of their routine care

Interventions

  • Otherpatient included in experimental groupe will view the video excerpt, a playtime, a drawing activities

    Patients included in the videodrama arm will participate in a total of 18 videodrama sessions, with one session per week. Each session will include a patient welcome period, the viewing of a video excerpt (in slow motion or not), a playtime, a drawing period, and a group closing session. For the play and drawing activities, the same materials will be provided in each department and for each group, including small figurines, animals, shapes (such as cubes, triangles, circles), small plush toys, markers, colored pencils, and A4 white sheets of paper.

07

What researchers measure

Primary outcomes

  1. Dunn Sensory Profile questionnaire

    Sensory atypicality frequency will be assessed using the Dunn Sensory Profile questionnaire, describing child behavior in various sensory experiences

    Time frame: 9 months

Secondary outcomes

  1. Cars-T questionnaire

    Observe improvements in social skills (interaction and communication) in children with ASD, assessed by the Cars-T questionnaire,

    Time frame: 9 months

  2. Sceno Test

    Observation of the emergence of a symbolic game. This emergence will be evaluated by the passation of the scenotest, a test which reveals the different modalities of integration of the game.

    Time frame: 9 months

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Mar 2027, 39 months after the start.

Of 355 non-industry interventional studies with no phase under Autistic Disorder, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 39 months is above that.

Counting every sponsor, half of 367 studies reached it within 26 months; a quarter within 13 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2024
First posted
Jun 5, 2024
StartActual
Dec 4, 2023
Primary completionEst.
Mar 4, 2027
CompletionEst.
Mar 4, 2027
Last update
Feb 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06443320
Lead sponsor
Centre Hospitalier Intercommunal Robert Ballanger
Responsible party
Sponsor
First posted
Jun 5, 2024
Start date
Dec 4, 2023
Primary completion
Mar 4, 2027 (estimated)
Completion
Mar 4, 2027 (estimated)
Last update
Feb 6, 2025

Study contacts

Constance LEMARCHAND
Contact
constance.lemarchand@ght-gpne.fr
0182372332

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion